Press Releases August 6, 2026 07:00 AM

CareCloud Reports Second Quarter 2026 Results

CareCloud Reports 16% Revenue Growth and Ninth Consecutive Quarter of GAAP Profitability in Q2 2026 with Strategic Expansion into Compliance Market

By Nina Shah
Share
Twitter Reddit Facebook LinkedIn
CCLD

CareCloud, Inc. announced its Q2 2026 financial results showing 16% revenue growth to $31.9 million and sustained profitability with a GAAP net income of $1.1 million. The company expanded its product portfolio by acquiring Empower Healthcare & Compliance Partners, entering the compliance and audit-defense market. CareCloud reaffirmed its full-year 2026 guidance and highlighted investments in AI-driven solutions and strategic acquisitions to fuel future growth.

CareCloud Reports Second Quarter 2026 Results
CCLD
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Q2 2026 revenue increased 16% year-over-year to $31.9 million, with nine consecutive quarters of positive GAAP net income.
  • Acquisition of Empower Healthcare expanded CareCloud's offerings to include compliance and audit-defense services, targeting over 40,000 providers in its network.
  • Company invests in AI capabilities and cross-selling opportunities to enhance platform value and operational efficiency.
  • Impacted sectors include healthcare technology, healthcare providers, artificial intelligence in healthcare, and regulatory compliance services.

Revenue Grows 16%; Ninth Consecutive Quarter of Positive GAAP Net Income

SOMERSET, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD), a leader in AI-powered healthcare technology and revenue cycle management solutions for medical practices and health systems nationwide, today announced financial results for the quarter ended June 30, 2026 and reaffirmed its full-year guidance.

Second Quarter 2026 Financial Highlights:

  • Revenue of $31.9 million, compared to $27.4 million in Q2 2025
  • GAAP net income of $1.1 million, compared to $2.9 million in Q2 2025
  • GAAP EPS of $0.00 per share, compared to $0.04 per share in Q2 2025
  • Adjusted EBITDA of $5.9 million, compared to $6.5 million in Q2 2025

Year-to-date 2026 Highlights:

  • Revenue of $63.2 million, compared to $55.0 million in the same period last year
  • GAAP net income of $2.0 million, compared to $4.9 million in the same period last year 
  • GAAP EPS of ($0.01) per share, compared to $0.02 per share in the same period last year
  • Adjusted EBITDA of $11.3 million, compared to $12.1 million in the same period last year

Key Second Quarter Accomplishments:

  • Compliance and Audit-Defense Market Entry: Expanded the product portfolio through the acquisition of Empower Healthcare & Compliance Partners, opening a new growth opportunity by bringing trusted compliance, audit-defense, and regulatory expertise to CareCloud's network of more than 40,000 providers.
  • Full Redemption of Series B Preferred Stock: Completed the redemption of all outstanding Series B Preferred Stock on May 15, 2026.
  • Sustained Profitability: Delivered the ninth consecutive quarter of positive GAAP net income.

Management Commentary

“This quarter we grew revenue 16%, delivered our ninth consecutive quarter of positive GAAP net income, and entered the compliance and audit-defense market through our acquisition of Empower Healthcare. We're investing deliberately in what we believe defines our next phase of growth — our AI solutions, our expanding capabilities, and the cross-sell opportunity across our more than 40,000 providers.” — Stephen Snyder, Chief Executive Officer, CareCloud

“Our AI and acquisition strategies have become a single, unified growth engine. Every platform we bring into CareCloud becomes smarter, faster, and more valuable when we layer in our AI capabilities. We are still in the early innings of unlocking the cross-sell potential across our expanded client base, and we are increasingly seeing customers adopt our AI-enabled offerings.” — A. Hadi Chaudhry, Chief Strategy Officer, CareCloud

"As expected, profitability this quarter reflects deliberate investments we are making today — increased R&D spending on our AI-enabled capabilities and increased interest expense from simplifying our capital structure through the Series B redemption — that we believe will deliver returns over time. We expect these investments to enhance scalability, improve operational efficiency, and support long-term margin expansion." — Norman Roth, Interim Chief Financial Officer and Corporate Controller, CareCloud

2026 Outlook

The Company is reaffirming its guidance for calendar year 2026.

For the Fiscal Year Ending December 31, 2026Full Year 2026 GuidanceRevenue$128 – $132 millionAdjusted EBITDA$29 – $31 millionGAAP Net Income Per Share (EPS)$0.20 – $0.23


Our expectations regarding future profitability, including adjusted EBITDA and earnings-per-share guidance, are based on management’s current beliefs and assumptions regarding, among other things, the signing and continuation of certain client and vendor relationships, the anticipated timing and scope of client projects, and our timely execution of integration and expense-management initiatives intended to align our cost structure with those objectives.

Conference Call Information

CareCloud management will host a live conference call today, August 6, 2026, at 8:30 a.m. Eastern Time to discuss second quarter 2026 results and the Company’s 2026 strategy.

Webcast: ir.carecloud.com/events
Dial-in (Audio Only): 201-389-0920 | Reference: “CareCloud, Inc. Second Quarter 2026 Results Conference Call.”

Replay Dial-in: 412-317-6671 | Access Code: 13761329 (available approximately 3 hours after the call).

About CareCloud

CareCloud brings disciplined innovation to the business of healthcare. Our suite of AI and technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve the patient experience. More than 40,000 providers count on CareCloud to help them improve patient care, while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at carecloud.com.

Follow CareCloud on LinkedIn, X and Facebook.

For additional information, please visit our website at carecloud.com. To listen to video presentations by CareCloud’s management team, read recent press releases and view the latest investor presentation, please visit ir.carecloud.com.

Contacts

Company Contact:
Norman Roth
Interim Chief Financial Officer and Corporate Controller
CareCloud, Inc.
[email protected] Contact:
Stephen Snyder
Chief Executive Officer
CareCloud, Inc.
[email protected]  

Use of Non-GAAP Financial Measures

In our earnings releases, prepared remarks, conference calls, slide presentations and webcasts, we use and discuss non-GAAP financial measures, as defined by SEC Regulation G. The GAAP financial measure most directly comparable to each non-GAAP financial measure used or discussed and a reconciliation of the differences between each non-GAAP financial measure and the comparable GAAP financial measure, are included in this press release after the condensed consolidated financial statements. Our earnings press releases containing such non-GAAP reconciliations can be found in the Investor Relations section of our web site at ir.carecloud.com.

Forward-Looking Statements

This press release contains various forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements relate to anticipated future events, future results of operations or future financial performance. In some cases, you can identify forward-looking statements by terminology such as “may,” “might,” “will,” “shall,” “should,” “could,” “intends,” “expects,” “plans,” “goals,” “projects,” “anticipates,” “believes,” “seeks,” “estimates,” “forecasts,” “predicts,” “possible,” “potential,” “target,” or “continue” or the negative of these terms or other comparable terminology.

Our operations involve risks and uncertainties, many of which are outside our control and any one of which, or a combination of which, could materially affect our results of operations and whether the forward-looking statements ultimately prove to be correct. Forward-looking statements in this press release include, without limitation, statements reflecting management's expectations for future financial performance and operating expenditures, expected growth, profitability and business outlook, the impact of pandemics on our financial performance and business activities and the expected results from the integration of our acquisitions.

These forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are only predictions, are uncertain and involve substantial known and unknown risks, uncertainties and other factors which may cause our (or our industry’s) actual results, levels of activity or performance to be materially different from any future results, levels of activity or performance expressed or implied by these forward-looking statements. New risks and uncertainties emerge from time to time and it is not possible for us to predict all of the risks and uncertainties that could have an impact on the forward-looking statements, including without limitation, risks and uncertainties relating to the Company’s ability to manage growth, migrate newly acquired customers and retain new and existing customers, maintain cost-effective global operations, increase operational efficiency and reduce operating costs, predict and properly adjust to changes in reimbursement and other industry regulations and trends, retain the services of key personnel, develop new technologies, upgrade and adapt legacy and acquired technologies to work with evolving industry standards, compete with other companies’ products and services competitive with ours, manage and keep our information systems secure and other important risks and uncertainties referenced and discussed under the heading titled “Risk Factors” in the Company’s filings with the Securities and Exchange Commission.

The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not assume any obligations to update the forward-looking statements provided to reflect events that occur or circumstances that exist after the date on which they were made.

CARECLOUD, INC.CONDENSED CONSOLIDATED BALANCE SHEETSAS OF JUNE 30, 2026 AND DECEMBER 31, 2025($ in thousands, except share and per share amounts)          June 30,   December 31,    2026   2025    (Unaudited)     ASSETS        Current assets:        Cash $13,395  $3,117 Restricted cash  -   500 Accounts receivable - net  14,117   15,062 Contract asset  3,426   3,664 Inventory  471   507 Current assets - related party  16   16 Prepaid expenses and other current assets  2,758   2,872 Total current assets  34,183   25,738 Property and equipment - net  7,259   7,775 Operating lease right-of-use assets  4,864   3,106 Intangible assets - net  14,929   18,968 Goodwill  31,835   31,442 Other assets  779   569 TOTAL ASSETS $93,849  $87,598 LIABILITIES AND SHAREHOLDERS' EQUITY        Current liabilities:        Accounts payable $6,071  $6,937 Accrued compensation  3,846   4,136 Accrued expenses  5,943   5,970 Operating lease liability (current portion)  1,573   927 Deferred revenue (current portion)  4,507   4,148 Term loans and other (current portion)  10,756   728 Contingent consideration (current portion)  400   909 Dividend payable  392   668 Total current liabilities  33,488   24,423 Term loans and other  29,223   441 Borrowings under line of credit  9,000   - Contingent consideration  290   232 Operating lease liability  3,462   2,187 Deferred revenue  934   809 Deferred tax liability  50   - Total liabilities  76,447   28,092 COMMITMENTS AND CONTINGENCIES        SHAREHOLDERS' EQUITY:        Preferred stock, $0.001 par value - authorized 7,000,000 shares. Series A, issued and outstanding 984,530 shares at June 30, 2026 and December 31, 2025. Series B, issued and outstanding 0 and 1,511,372 shares at June 30, 2026 and December 31, 2025, respectively.  1   2 Common stock, $0.001 par value - authorized 85,000,000 shares. Issued 43,234,658 and 43,178,748 shares at June 30, 2026 and December 31, 2025, respectively. Outstanding 42,493,859 and 42,437,949 shares at June 30, 2026 and December 31, 2025, respectively.  43   43 Additional paid-in capital  75,735   119,936 Accumulated deficit  (53,788)  (55,832)Accumulated other comprehensive loss  (3,927)  (3,981)Less: 740,799 common shares held in treasury, at cost at June 30, 2026 and December 31, 2025  (662)  (662)Total shareholders' equity  17,402   59,506 TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY $93,849  $87,598 


CARECLOUD, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2026 AND 2025($ in thousands, except share and per share amounts)  Three Months Ended  Six Months Ended   June 30,  June 30,   2026  2025  2026  2025 NET REVENUE $31,880  $27,377  $63,150  $55,009 OPERATING EXPENSES:                Direct operating costs  17,457   14,480   34,307   29,944 Selling and marketing  1,300   1,118   2,714   2,249 General and administrative  5,370   4,358   10,866   8,690 Research and development  2,194   1,020   4,610   2,255 Change in contingent consideration  (34)  -   23   - Depreciation and amortization  3,731   3,382   7,768   6,719 Restructuring costs  -   23   -   137 Total operating expenses  30,018   24,381   60,288   49,994 OPERATING INCOME  1,862   2,996   2,862   5,015 OTHER:                Interest income  73   51   83   93 Interest expense  (815)  (68)  (873)  (126)Other income (expense) - net  104   (35)  126   (49)INCOME BEFORE PROVISION FOR INCOME TAXES  1,224   2,944   2,198   4,933 Income tax provision  102   42   154   83 NET INCOME $1,122  $2,902  $2,044  $4,850                  Preferred stock dividend  941   1,365   2,306   4,176 NET INCOME (LOSS) ATTRIBUTABLE TO COMMON SHAREHOLDERS $181  $1,537  $(262) $674                  Net income (loss) per common share: basic and diluted $0.00  $0.04  $(0.01) $0.02 Weighted-average common shares used to compute basic and diluted loss per share  42,493,449   42,321,629   42,482,758   33,118,912 


CARECLOUD, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)FOR THE SIX MONTHS ENDED JUNE 30, 2026 AND 2025($ in thousands)          2026   2025 OPERATING ACTIVITIES:         Net income $2,044  $4,850  Adjustments to reconcile net income to net cash provided by operating activities:         Depreciation and amortization  7,858   6,855  Lease amortization  896   901  Provision for expected credit losses  118   169  Provision for deferred income taxes  50   -  Foreign exchange loss  15   1  Interest accretion  208   219  Change in contingent consideration  23   -  Stock-based compensation expense  128   219  Changes in operating assets and liabilities:         Accounts receivable  827   (958) Contract asset  238   411  Inventory  36   51  Other assets  73   (838) Accounts payable and other liabilities  (2,146)  377  Deferred revenue  316   264  Net cash provided by operating activities  10,684   12,521 INVESTING ACTIVITIES:         Purchases of property and equipment  (937)  (1,786) Capitalized software and other intangible assets  (1,620)  (1,677) Payment for acquisitions  (681)  (40) Net cash used in investing activities  (3,238)  (3,503)FINANCING ACTIVITIES:         Preferred stock dividends paid  (6,436)  (3,317) Payment of contingent consideration  (618)  -  Payment of tax withholding on stock issued to employees  (1)  (22) Proceeds from term loan  39,739   -  Repayments of notes payable and term loan  (1,191)  (355) Redemption of Series B Preferred Stock  (38,169)  -  Proceeds from line of credit  9,000   -  Net cash provided by (used in) financing activities  2,324   (3,694)EFFECT OF EXCHANGE RATE CHANGES ON CASH AND RESTRICTED CASH  8   (29)NET INCREASE IN CASH AND RESTRICTED CASH  9,778   5,295 CASH AND RESTRICTED CASH - Beginning of the period  3,617   5,145 CASH - End of the period $13,395  $10,440 SUPPLEMENTAL NONCASH INVESTING AND FINANCING ACTIVITIES:         Conversion of Series A Preferred Stock and accrued dividends to common stock $-  $2,435  Dividends declared, not paid $392  $714 SUPPLEMENTAL INFORMATION - Cash paid during the period for:         Income taxes $158  $144  Interest $517  $44 


RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
TO COMPARABLE GAAP MEASURES (UNAUDITED)

The following is a reconciliation of the non-GAAP financial measures used by us to describe our financial results determined in accordance with accounting principles generally accepted in the United States of America (“GAAP”). An explanation of these measures is also included below under the heading “Explanation of Non-GAAP Financial Measures.”

While management believes that these non-GAAP financial measures provide useful supplemental information to investors regarding the underlying performance of our business operations, investors are reminded to consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies, and management may utilize other measures to illustrate performance in the future. Non-GAAP measures have limitations in that they do not reflect all of the amounts associated with our results of operations as determined in accordance with GAAP.

Adjusted EBITDA to GAAP Net Income

Set forth below is a reconciliation of our “adjusted EBITDA” to our GAAP net income.

  Three Months Ended June 30,  Six Months Ended June 30,   2026  2025  2026  2025   ($ in thousands) Net revenue $31,880  $27,377  $63,150  $55,009                  GAAP net income  1,122   2,902   2,044   4,850                  Provision for income taxes  102   42   154   83 Net interest expense  742   17   790   33 Foreign exchange loss / other expense  54   41   86   60 Stock-based compensation expense  64   111   128   219 Depreciation and amortization  3,731   3,382   7,768   6,719 Change in contingent consideration  (34)  -   23   - Transaction and integration costs  166   11   324   23 Restructuring costs  -   23   -   137 Adjusted EBITDA $5,947  $6,529  $11,317  $12,124 


Non-GAAP Adjusted Operating Income to GAAP Operating Income

Set forth below is a reconciliation of our non-GAAP “adjusted operating income” and non-GAAP “adjusted operating margin” to our GAAP operating income and GAAP operating margin.

  Three Months Ended June 30,  Six Months Ended June 30,   2026  2025  2026  2025   ($ in thousands) Net revenue $31,880  $27,377  $63,150  $55,009                  GAAP net income  1,122   2,902   2,044   4,850 Provision for income taxes  102   42   154   83 Net interest expense  742   17   790   33 Other (income) expense - net  (104)  35   (126)  49 GAAP operating income  1,862   2,996   2,862   5,015 GAAP operating margin  5.8%  10.9%  4.5%  9.1%                 Stock-based compensation expense  64   111   128   219 Amortization of purchased intangible assets  945   193   1,873   282 Transaction and integration costs  166   11   324   23 Change in contingent consideration  (34)  -   23   - Restructuring costs  -   23   -   137 Non-GAAP adjusted operating income $3,003  $3,334  $5,210  $5,676 Non-GAAP adjusted operating margin  9.4%  12.2%  8.3%  10.3%


Non-GAAP Adjusted Net Income to GAAP Net Income

Set forth below is a reconciliation of our non-GAAP “adjusted net income” and non-GAAP “adjusted net income per share” to our GAAP net income and GAAP net income per share.

  Three Months Ended June 30,  Six Months Ended June 30,   2026  2025  2026  2025   ($ in thousands ) GAAP net income $1,122  $2,902  $2,044  $4,850                  Foreign exchange loss / other expense  54   41   86   60 Stock-based compensation expense  64   111   128   219 Amortization of purchased intangible assets  945   193   1,873   282 Transaction and integration costs  166   11   324   23 Change in contingent consideration  (34)  -   23   - Restructuring costs  -   23   -   137 Income tax expense related to goodwill  50   -   50   - Non-GAAP adjusted net income $2,367  $3,281  $4,528  $5,571 


  Three Months Ended June 30,  Six Months Ended June 30,   2026  2025  2026  2025 GAAP net income (loss) attributable to common shareholders, per share $0.00  $0.04  $(0.01) $0.02 Impact of preferred stock dividend  0.03   0.03   0.06   0.09 Net income per end-of-period share  0.03   0.07   0.05   0.11                  Foreign exchange loss / other expense  0.00   0.00   0.00   0.00 Stock-based compensation expense  0.01   0.00   0.01   0.01 Amortization of purchased intangible assets  0.02   0.00   0.04   0.01 Transaction and integration costs  0.00   0.00   0.01   0.00 Change in contingent consideration  0.00   0.00   0.00   - Restructuring costs  -   0.00   -   0.00 Income tax expense related to goodwill  0.00   -   0.00   - Non-GAAP adjusted earnings per share $0.06  $0.07  $0.11  $0.13                  End-of-period common shares  42,493,859   42,322,039   42,493,859   42,322,039 


For purposes of determining non-GAAP adjusted earnings per share, the Company used the number of common shares outstanding as of June 30, 2026 and 2025. Non-GAAP adjusted earnings per share does not take into account dividends declared or earned on preferred stock.

Net cash provided by operating activities to free cash flow

Set forth below is a reconciliation of our non-GAAP “free cash flow” to our GAAP net cash provided by operating activities.

  Three Months Ended June 30,  Six Months Ended June 30,   2026  2025  2026  2025   ($ in thousands) Net cash provided by operating activities $7,073  $7,408  $10,684  $12,521                  Purchases of property and equipment  (525)  (1,162)  (937)  (1,786)Capitalized software and other intangible assets  (800)  (831)  (1,620)  (1,677)Free cash flow $5,748  $5,415  $8,127  $9,058                  Net cash used in investing activities 1 $(2,006) $(1,993) $(3,238) $(3,503)Net cash provided by (used in) financing activities $4,474  $(1,762) $2,324  $(3,694)                 1. Net cash used in investing activities includes payments for acquisitions, purchases of property and equipment and capitalized software and other intangible assets. Purchases of property and equipment and capitalized software and other intangible assets are included in our computation of free cash flow. 

Explanation of Non-GAAP Financial Measures

We report our financial results in accordance with accounting principles generally accepted in the United States of America, or GAAP. However, management believes that, in order to properly understand our short-term and long-term financial and operational trends, investors may wish to consider the impact of certain non-cash or non-recurring items, when used as a supplement to financial performance measures in accordance with GAAP. These items result from facts and circumstances that vary in frequency and impact on continuing operations. Management also uses results of operations before such items to evaluate the operating performance of CareCloud and compare it against past periods, make operating decisions and serve as a basis for strategic planning. These non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts. Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors.

Management uses adjusted EBITDA, adjusted operating income, adjusted operating margin, and non-GAAP adjusted net income to provide an understanding of aspects of operating results before the impact of investing and financing charges and income taxes. Adjusted EBITDA may be useful to an investor in evaluating our operating performance and liquidity because this measure excludes non-cash expenses as well as expenses pertaining to investing or financing transactions. Management defines “adjusted EBITDA” as the sum of GAAP net income before provision for income taxes, net interest expense, other (income) expense, stock-based compensation expense, depreciation and amortization, integration costs, transaction costs, and change in contingent consideration.

Management defines “non-GAAP adjusted operating income” as the sum of GAAP operating income before stock-based compensation expense, amortization of purchased intangible assets, integration costs, transaction costs, and change in contingent consideration, and “non-GAAP adjusted operating margin” as non-GAAP adjusted operating income divided by net revenue.

Management defines “non-GAAP adjusted net income” as the sum of GAAP net income before stock-based compensation expense, amortization of purchased intangible assets, other (income) expense, integration costs, transaction costs, change in contingent consideration, any tax impact related to these preceding items and income tax expense related to goodwill, and “non-GAAP adjusted net income per share” as non-GAAP adjusted net income divided by common shares outstanding at the end of the period, including the shares which were issued but are subject to forfeiture and considered contingent consideration.

Management considers all of these non-GAAP financial measures to be important indicators of our operational strength and performance of our business and a good measure of our historical operating trends, in particular the extent to which ongoing operations impact our overall financial performance.

In addition to items routinely excluded from non-GAAP EBITDA, management excludes or adjusts each of the items identified below from the applicable non-GAAP financial measure referenced above for the reasons set forth with respect to that excluded item:

Foreign exchange loss/other expense. Other expense is excluded because foreign currency gains and losses and other non-operating expenses are expenditures that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expense is partially outside of our control. Foreign currency gains and losses are based on global market factors which are unrelated to our performance during the period in which the gains and losses are recorded.

Stock-based compensation expense. Stock-based compensation expense is excluded because this is primarily a non-cash expenditure that management does not consider part of ongoing operating results when assessing the performance of our business, and also because the total amount of the expenditure is partially outside of our control because it is based on factors such as stock price, volatility, and interest rates, which may be unrelated to our performance during the period in which the expenses are incurred.

Amortization of purchased intangible assets. Purchased intangible assets are amortized over their estimated useful lives and generally cannot be changed or influenced by management after the acquisition. Accordingly, this item is not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are recorded.

Contingent consideration. Contingent consideration represents the portion of consideration payable to the seller of some of our acquisitions, the amount of which is based on the achievement of defined performance measures contained in the purchase agreements. Contingent consideration is adjusted to fair value at the end of each reporting period. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Transaction costs. Transaction costs are upfront costs related to acquisitions and related transactions, such as brokerage fees, pre-acquisition accounting costs and legal fees, and other upfront costs related to specific transactions. Management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Integration costs. Integration costs are severance payments for certain employees relating to our acquisitions and exit costs related to terminating leases and other contractual agreements. Accordingly, management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Restructuring costs. Restructuring costs primarily consist of severance and separation costs associated with the optimization of the Company’s operations and profitability improvements. Management believes that such expenses do not have a direct correlation to future business operations, and therefore, these costs are not considered by management in making operating decisions. Management does not believe such charges accurately reflect the performance of our ongoing operations for the period in which such charges are incurred.

Income tax expense related to goodwill. Income tax expense resulting from the amortization of goodwill related to our acquisitions represents a charge to record the tax effect resulting from amortizing goodwill over 15 years for tax purposes. Goodwill is not amortized for GAAP reporting. This expense is not anticipated to result in a cash payment.

Free cash flow. Management believes that free cash flow, which measures our ability to generate additional cash from our business operations, is an important financial measure for use in evaluating the Company's financial performance. Free cash flow should be considered in addition to, rather than as a substitute for, consolidated net operating results as a measure of our performance and net cash provided by operating activities as a measure of our liquidity. Additionally, the Company's definition of free cash flow is limited, in that it does not represent residual cash flows available for discretionary expenditures, due to the fact that the measure does not deduct the payments required for debt service and other contractual obligations or payments made for business acquisitions. Therefore, we believe it is important to view free cash flow as a measure that provides supplemental information to our condensed consolidated statements of cash flows.


Risks

  • Profitability impacted by increased R&D spending on AI capabilities and interest expense due to recent debt refinancing and preferred stock redemption.
  • Execution risk related to integration of acquisitions and realization of cross-sell opportunities across client base.
  • Potential exposure to changes in reimbursement policies, industry regulations, and competition in health technology and compliance markets.

More from Press Releases

Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update Aug 6, 2026 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update Aug 6, 2026 Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma Aug 6, 2026 Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. Aug 6, 2026 Belite Bio to Host Webcast on August 13, 2026, to Discuss Second Quarter 2026 Financial Results Aug 6, 2026